US Consumer Health Industry In 2023: With Supply Chain Concerns Constant, Challenges Loom Larger

OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight begins reporting from those talks with outlook for supply chain nd production disruptions and prevalence of COVID-19 and other widespread viruses.

• Source: Shutterstock

The US consumer health products industries are ready in 2023 to continue providing essential staples for health and nutrition needs while potentially expanding its reach in response to increased opportunities or adjusting to a rule imposing a gate-keeping step for the first time.

Across consumer health sectors, businesses in 2023 also face the likelihood for continued supply chain and production disruptions, some linked to countries’ responses to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Supply Chain

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

Rapidly Changing Market Demands Quick Study From Consumer Health, Personal Care Marketers

 

“It is shifting so quickly. It's shifting underneath our feet,” says NielsenIQ wellness VP Sherry Frey. Even comparing the past year to the preceding eight, “it's just accelerating quicker and quicker, and one of the biggest areas is online.”

China Distribution Disruption Drags Kenvue Results

 

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

Tariff War Should Steer US Firms To Mapping Out North American Supply Chains

 

Supplies from Mexico and Canada could become even more important to US firms as well as more reliable than their current systems, says Rob Handfield, Bank of America distinguished professor of supply chain management at NC State.

More from HBW Insight

Shiseido’s Key Priorities: Recover Drunk Elephant, Accelerate NARS Amid US Prestige Slowdown

 

Shiseido’s Drunk Elephant premium skin care range – acquired in 2019 – and its NARS brand dragged sales in the Americas region down almost 20% in the first quarter, the firm reported in a 12 May earnings presentation.

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”